CD38hiCD19dim Cells in Lymph Nodes as Prognostic Biomarkers for Stage III Melanoma

A study of 29 patients with stage III melanoma receiving adjuvant anti-PD-1 therapy, analyzing cellular composition in regional lymph nodes via mass cytometry. The dataset includes CyTOF data from pre-treatment surgical specimens and references NanoString bulk gene expression data from an untreated cohort of 125 patients. The research was authored by Ieva Ailte and published on figshare in May 2026.

Use Cases

• Identify prognostic biomarkers for immunotherapy response based on proportions of CD103+PD-1+CD8+ T cells.
• Associate baseline immune cell infiltration with distant metastasis-free survival based on CD38hiCD19dim plasmablast-like cells.
• Characterize 'B cell excluded' tumor subgroups based on tumor-infiltrating lymphocyte pathology scores.
• Validate CyTOF-derived immune trends using bulk gene expression data from an independent cohort.

Strengths

• Includes data from a defined clinical cohort of 29 patients receiving adjuvant anti-PD-1 therapy.
• Correlates findings with a larger validation cohort of 125 patients using NanoString gene expression data.
• Uses high-dimensional mass cytometry (CyTOF) to determine cellular composition.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The primary data file is a 130.1 KB PDF, suggesting the underlying numerical data may not be directly accessible.
• Data may reflect the specific bias inherent to the single study's patient cohort and methodology.

Provenance

Source

figshare

Collection Method

Mass cytometry (CyTOF) on pre-treatment surgical lymph node specimens from a clinical cohort.

Time Range

null

Freshness

Last updated 2026-05-04 04:18:50.

Geography

null